Central nervous system international prognostic index impacts overall survival in diffuse large b-cell lymphoma treated with r-chop in a third level cancer center from Mexico: a survey of 642 patients
Rev. invest. clín
;
73(4): 231-237, Jul.-Aug. 2021. tab, graf
Artículo
en Inglés
| LILACS
| ID: biblio-1347569
ABSTRACT
Background:
Central nervous system international prognosis index (CNS-IPI) is validated in European and the USA cancer databases. However, no validation has been done in Mexican population.Objective:
The objective of the study was to assess the impact of the CNS-IPI on central nervous system (CNS) relapse and survival in Mexican patients with diffuse large B-cell lymphoma (DLBCL).Methods:
In this retrospective analysis, clinical, biochemical, and histological variables and the CNS-IPI were analyzed.Results:
Six hundred and forty-two patients with DBLCL were included in the study. The mean ± SD age was 56.8 ± 14.9 years. Most had an ECOG of 0-1 75% (n = 484) had absence of B-symptoms and advanced disease (clinical stage III-IV, n = 433, 67.4%). According to the CNS-IPI, almost one-half were in the low-risk category. According to the CNS-IPI, CNS relapse rate was 1.36% (95% CI 83.2-92.8), 3.1% (95% CI 132.4-162.8), and 7.4% (95% CI 61-91) for patients in the low-, intermediate-, and high-risk categories, respectively. The median overall survival in the high-risk group (CNS-IPI) was 22 months, and it has not been achieved after 80 months of follow-up for the other groups.Conclusions:
CNS-IPI was associated with survival; therefore, we propose its use as a prognostic tool for prospective validation.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Linfoma de Células B Grandes Difuso
/
Neoplasias del Sistema Nervioso Central
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Adulto
/
Anciano
/
Humanos
País/Región como asunto:
México
Idioma:
Inglés
Revista:
Rev. invest. clín
Asunto de la revista:
Medicina
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
México
Institución/País de afiliación:
Instituto Nacional de Cancerología/MX
Similares
MEDLINE
...
LILACS
LIS